
Stereotaxis Inc (STXS) Stock Forecast & Price Target
Stereotaxis Inc (STXS) Analyst Ratings
Bulls say
Stereotaxis Inc. is projected to achieve significant revenue growth, with forecasts indicating increases to $43 million for Systems, $12 million for Disposables, Royalty, and Sublease, and $31 million for service and accessories by FY26, primarily driven by new system sales and catheter utilization. The company reported a substantial revenue rise of 95% year-over-year to $8.8 million in the second quarter, with recurring revenue bolstered by the Map-iT and MAGiC catheter launches and anticipated to grow further. Additionally, notable regulatory advancements and the upcoming launch of the GenesisX system are expected to enhance market presence and drive ongoing financial performance, supporting the outlook for exceeding $10 million in average quarterly revenue by FY26.
Bears say
Stereotaxis, Inc. is currently facing several challenges that contribute to a negative outlook on its stock. The company reported a net loss of $3.8 million, alongside a significant reliance on the Disposables, service, and accessories stream for revenue generation, which is susceptible to market fluctuations and reimbursement changes. Additionally, ongoing issues such as delays in new product approvals, supply chain constraints, and increasing competition from both manual and robotic approaches may hinder revenue growth and profitability, further complicating the company’s financial stability in the near term.
This aggregate rating is based on analysts' research of Stereotaxis Inc and is not a guaranteed prediction by Public.com or investment advice.
Stereotaxis Inc (STXS) Analyst Forecast & Price Prediction
Start investing in Stereotaxis Inc (STXS)
Order type
Buy in
Order amount
Est. shares
0 shares